<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palladini, G.</style></author><author><style face="normal" font="default" size="100%">Dispenzieri, A.</style></author><author><style face="normal" font="default" size="100%">Gertz, M.A.</style></author><author><style face="normal" font="default" size="100%">Kumar, S.</style></author><author><style face="normal" font="default" size="100%">Wechalekar, A.</style></author><author><style face="normal" font="default" size="100%">Hawkins, P.N.</style></author><author><style face="normal" font="default" size="100%">Schönland, S.</style></author><author><style face="normal" font="default" size="100%">Hegenbart, U.</style></author><author><style face="normal" font="default" size="100%">Comenzo, R.</style></author><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Jaccard, A.</style></author><author><style face="normal" font="default" size="100%">Klersy, C.</style></author><author><style face="normal" font="default" size="100%">Merlini, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871772553&amp;doi=10.1200%2fJCO.2011.37.7614&amp;partnerID=40&amp;md5=b4a7d4b2e78f9e774e2e34fce1602f60</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">30</style></volume><pages><style face="normal" font="default" size="100%">4541 - 4549</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Purpose: To identify the criteria for hematologic and cardiac response to treatment in immunoglobulin light chain (AL) amyloidosis based on survival analysis of a large patient population. Patients and Methods: We gathered for analysis 816 patients with AL amyloidosis from seven referral centers in the European Union and the United States. A different cohort of 374 patients prospectively evaluated at the Pavia Amyloidosis Research and Treatment Center was used for validation. Data was available for all patients before and 3 and/or 6 months after initiation of first-line therapy. The prognostic relevance of different criteria for hematologic and cardiac response was assessed. Results: There was a strong correlation between the extent of reduction of amyloidogenic free light chains (FLCs) and improvement in survival. This allowed the identification of four levels of response: amyloid complete response (normal FLC ratio and negative serum and urine immunofixation), very good partial response (difference between involved and uninvolved FLCs [dFLC] &lt; 40 mg/L), partial response (dFLC decrease &gt; 50%), and no response. Cardiac involvement is the major determinant of survival, and changes in cardiac function after therapy can be reliably assessed using the cardiac biomarker N-terminal natriuretic peptide type B (NT-proBNP). Changes in FLC and NT-proBNP predicted survival as early as 3 months after treatment initiation. Conclusion: This study identifies and validates new criteria for response to first-line treatment in AL amyloidosis, based on their association with survival in large patient populations, and offers surrogate end points for clinical trials. © 2012 by American Society of Clinical Oncology.</style></abstract><issue><style face="normal" font="default" size="100%">36</style></issue><notes><style face="normal" font="default" size="100%">Cited By :165Export Date: 21 February 2017</style></notes></record></records></xml>